Journal
NEUROSCIENCE
Volume 139, Issue 3, Pages 843-851Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2006.01.002
Keywords
arginine vasopressin; V1a receptor; oxytocin receptor; V1a antagonist; oxytocin antagonist; female sexual behavior
Categories
Funding
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056157] Funding Source: NIH RePORTER
- NIMH NIH HHS [MH56157] Funding Source: Medline
Ask authors/readers for more resources
Previous studies have found that central administration of arginine vasopressin and arginine vasopressin receptor Via antagonists respectively inhibited and stimulated receptivity but did not examine effects on other aspects of female sexual behavior. Central oxytocin facilitates both proceptive and receptive components of sexual behavior and diminishes male-directed agonistic behavior. The present study examined i.c.v.-administered arginine vasopressin and V1a antagonist effects on proceptive, receptive and agonistic behaviors, and interactions with oxytocin. In experiment 1, rats were primed s.c. with 2 mu g estradiol benzoate x2 days and with 500 mu g of progesterone on day 3. Arginine vasopressin (0.2, 0.4 mu g) or normal saline vehicle was administered 5 h after progesterone treatment and sexual and agonistic behavior measured 30, 60 and 90 min later. Compared with saline, both doses of arginine vasopressin significantly decreased lordosis responses to mounting and hop-dart proceptive behavior and trended toward significantly increasing agonistic behaviors. In experiment 2, oxytocin (2 mu g) infusion just after arginine vasopressin (0.4 mu g) significantly increased lordoses and decreased agonistic behaviors but did not affect hopping and darting. In experiment 3, conducted in ovariectornized rats primed with estradiol benzoate (1 mu g/day s.c.x 2 days), i.c.v. infusion of 0.5 and 1.0 mu g of the selective Via antagonist, d(CH2)(5)Tyr-(Me)arginine vasopressin on day 3 significantly increased lordoses and trended toward increasing hopping and darting 4 and 6 h after i.c.v. treatment. In experiment 4, 1 mu g of the selective oxytocin antagonist, d(CH2)(5)[Tyr(Me)(2), Thr(4), Tyr-NH29]OVT given 1 h before d(CH2)(5)Tyr-(Me)arginine vasopressin (I ILg) significantly decreased lordoses. Previous studies indicate that arginine vasopressin contributes to light phase inhibition of female sexual behavior. Our findings suggest that arginine vasopressin may exert this effect through interactions that decrease oxytocin stimulation of sexual behavior and raise the question whether sex steroid conditions that stimulate sexual behavior may suppress central arginine vasopressin and Via receptor activity. (c) 2006 Published by Elsevier Ltd on behalf of IBRO.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available